Loading…
Clearmind Medicine Inc. is projected to rise to $2.67 by 2027, a +32% move from its current price of $2.03. CMND is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.91 | $2.03 | $2.16 | +0.02% |
| Jul 14 | $1.86 | $2.03 | $2.21 | +0.05% |
| Jul 15 | $1.83 | $2.03 | $2.26 | +0.07% |
| Jul 16 | $1.80 | $2.03 | $2.29 | +0.09% |
| Jul 17 | $1.78 | $2.03 | $2.33 | +0.11% |
| Jul 18 | $1.75 | $2.03 | $2.36 | +0.14% |
| Jul 19 | $1.73 | $2.03 | $2.39 | +0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.73 | $2.03 | $2.39 | +0.16% |
| Week 2 | $1.62 | $2.04 | $2.55 | +0.32% |
| Week 3 | $1.55 | $2.04 | $2.69 | +0.48% |
| Week 4 | $1.48 | $2.04 | $2.81 | +0.64% |
| Week 5 | $1.43 | $2.05 | $2.92 | +0.80% |
| Week 6 | $1.39 | $2.05 | $3.03 | +0.96% |
| Week 7 | $1.35 | $2.05 | $3.13 | +1.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Clearmind Medicine Inc. is a clinical stage pharmaceutical company that develops novel psychedelic medicines to treat under-served health problems. The company focuses on treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression.
It develops the MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. The company maintains strategic collaborations with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc.
and changed its name to Clearmind Medicine Inc. in March 2021. It was incorporated in 2017 and is headquartered in Vancouver, Canada.
CMND trades at $2.12 per share, with a market capitalization of $3.15M and a rank of 5427.
The near-term technical picture is neutral, with RSI14 at 30. The 50-day moving average is $3.93 and the 200-day moving average is $89.25.
Support is at $2.12 and resistance at $3.98. The 30-day price range runs from $1.37 to $3.28.
Forecasts imply upside potential across the horizon, with the average price rising from $2.12 in 2026 to $6.44 by 2050, and a 2050 max of $14.81. Sentiment shifts to BULLISH in most years after 2026, suggesting a favorable longer-term outlook despite near-term volatility.
A major floor 64.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 96.1% above — a clean break opens room to run.
A major ceiling 604.4% above — clearing it would confirm fresh momentum.
Key CMND support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CMND market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.13 | Sell | $2.12 | Sell |
| MA 10 | $2.22 | Sell | $2.27 | Sell |
| MA 20 | $2.64 | Sell | $2.58 | Sell |
| MA 50 | $3.60 | Sell | $4.65 | Sell |
| MA 100 | $6.70 | Sell | $21.90 | Sell |
| MA 200 | $82.70 | Sell | $109.03 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 30.99 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -93.82 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | -31.65 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -2.05 | Sell |
| Awesome (5,34) | -0.66 | Sell |
| Ultimate (7,14,28) | 26.62 | Buy |
| Momentum (10) | -0.46 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 2.02 | Buy |
| ADX (14) | 29.19 | Sell |
| ATR (14) | 0.17 | Info |
The 30-day technical picture is neutral overall.
RSI14 is 30, indicating potential near-term weakness or oversold conditions. The stock’s momentum indicators show the 50-day SMA at $3.93 and the 200-day SMA at $89.25, highlighting a wide gap between recent price action and longer-term trends.
Price levels to monitor include support at $2.12 and resistance at $3.98, with the 30-day price range spanning $1.37 to $3.28.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.03 | $2.03 | $2.91 | 0% | Neutral | |
| $1.94 | $2.67 | $3.98 | +32% | Bullish | |
| $1.96 | $2.86 | $4.55 | +41% | Bullish | |
| $2.05 | $3.16 | $5.27 | +56% | Bullish | |
| $1.81 | $2.92 | $5.07 | +44% | Bullish | |
| $1.39 | $2.35 | $4.22 | +16% | Neutral | |
| $1.47 | $2.59 | $4.79 | +27% | Bullish | |
| $1.61 | $2.95 | $5.62 | +45% | Bullish | |
| $1.99 | $3.80 | $7.42 | +87% | Bullish | |
| $2.11 | $4.19 | $8.38 | +107% | Bullish | |
| $2.27 | $5.05 | $11.09 | +149% | Bullish | |
| $2.79 | $6.21 | $14.28 | +206% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.03 | $2.03 | $2.46 | +0.00% |
| August 2026 | $1.75 | $2.12 | $2.68 | +4.56% |
| September 2026 | $1.69 | $2.07 | $2.67 | -2.36% |
| October 2026 | $1.56 | $1.94 | $2.54 | -6.42% |
| November 2026 | $1.63 | $2.05 | $2.72 | +5.48% |
| December 2026 | $1.70 | $2.16 | $2.91 | +5.72% |
Click any year to see its month-by-month CMND forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CMND is projected to trade between $2.03 and $2.91, averaging $2.03 — a potential gain of 0% from today's $2.03. A consolidation phase looks the most probable path here.
Clearmind Medicine Inc.'s 2027 outlook centres on $2.67, within a $1.94 to $3.98 range. That is up +32% on the projected 2026 average. That marks a +32% change versus current levels. Momentum favours further upside here.
By 2028, CMND could reach as high as $4.55, with a base case around $2.86 and support toward $1.96 — roughly +41% from $2.03. Buyers look set to stay in control over this stretch.
Expect CMND to range from $2.05 to $5.27 through 2029. The $3.16 average target implies a +56% move from current prices. That is up +10% on the projected 2028 average. Momentum favours further upside here.
The CMND price prediction for 2030 points to an average of $2.92 (low $1.81, high $5.07) — a potential gain of +44% on today's $2.03. Buyers look set to stay in control over this stretch.
In 2031, CMND is projected to trade between $1.39 and $4.22, averaging $2.35 — a potential gain of +16% from today's $2.03. That is -19% versus the projected 2030 average. Price action looks broadly range-bound.
Clearmind Medicine Inc.'s 2032 outlook centres on $2.59, within a $1.47 to $4.79 range. That is up +10% on the projected 2031 average. That marks a +27% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CMND could reach as high as $5.62, with a base case around $2.95 and support toward $1.61 — roughly +45% from $2.03. Momentum favours further upside here.
Expect CMND to range from $1.99 to $7.42 through 2034. The $3.80 average target implies a +87% move from current prices. That is up +29% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The CMND price prediction for 2035 points to an average of $4.19 (low $2.11, high $8.38) — a potential gain of +107% on today's $2.03. Momentum favours further upside here.
In 2040, CMND is projected to trade between $2.27 and $11.09, averaging $5.05 — a potential gain of +149% from today's $2.03. That is up +21% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Clearmind Medicine Inc.'s 2050 outlook centres on $6.21, within a $2.79 to $14.28 range. That is up +23% on the projected 2040 average. That marks a +206% change versus current levels. Momentum favours further upside here.
Investing $1,000 in CMND today (≈ 492.610837 CMND) could be worth
$3,057.83
+$2,057.83 (+206%) by 2050 · US Dollar
Based on the average projected CMND price of $6.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CMNDwould be worth at today's price.
$1,000 invested in CMND on Jul 10, 2025 (≈ 2.55102 CMND) would be worth
$5.18
-$994.82 (-99.5%) today · 0.01× · US Dollar
Based on a CMND entry price of $392 vs. today's $2.03.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.36 | $860.17 | -14.0% |
| 1 month ago | $3.2 | $634.37 | -36.6% |
| 3 months ago | $12.8 | $158.59 | -84.1% |
| 6 months ago | $21.6 | $93.98 | -90.6% |
| 1 year ago | $392 | $5.18 | -99.5% |
| All time (3.7y) ago | $70,800 | $0.03 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CMND forecast.
Our base-case forecast reaches $4.10 around 2035.
Implied market cap at $4.10: $6.09M
The multi-year forecast points to a bullish trajectory beyond 2026, with notable upside in later years. The 2027 average price is $2.77 and the 2027 max is $4.14, underpinning a bullish sentiment for that period; by 2028 the average rises to $3.02 and by 2029 to $3.29, with corresponding improvements in ROI (80s into mid-50s) and continuing bullish sentiment.
Key targets appear in 2030, where the average is $3.03 with a 43.1% ROI and a bullish outlook. By 2040, the average is projected to $5.31 with a 150.7% ROI, and by 2050 the average reaches $6.44 with a 203.7% ROI, both Bullish. The forecast also shows a 2031 average of $2.47 and a 2031 sentiment of NEUTRAL, illustrating modest pullbacks within an overall uptrend.
The asset exhibits annualized volatility of 100%, underscoring high risk and the potential for wide price swings. Drivers of the long-run outlook include elevated upside potential in the later horizon (2040–2050) and sustained bullish sentiment in many years, but the path includes years of neutrality or slower growth (e.g., 2031) and substantial volatility given the micro-cap profile.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $3.03 with a max of $5.27 and a min of $1.88, accompanied by a 43.1% ROI and bullish sentiment.
Forecasts indicate bullish sentiment in most years after 2026, with the average price rising to $6.44 by 2050 and ROIs up to 203.7%. However, 2026 shows ROI of 0% and 2031 is NEUTRAL, and the asset also has 100% annualized volatility, signaling high risk.
Yes. The 2050 forecast lists a max price of $14.81, with an average of $6.44 and a ROI of 203.7% in that year’s outlook.
Current price is $2.12 and market capitalization is $3.15M.
The 30-day range is $1.37 to $3.28.
Clearmind Medicine Inc. Community Discussion
0Share your Clearmind Medicine Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.